GlassScriptPhysician profile
Douglas Altenbern
NPI 1124005145
$799.89
in general payments reported to CMS, 2019-2025
23 companies · $279 in 2025
The $279 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.52 · 2021: $21.85 · 2022: $66.45 · 2023: $139 · 2024: $206 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $625.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $116.40 | 2025 | Orgovyx |
| Endo USA, INC. | $70.63 | 2025 | Xiaflex, Aveed |
| Urogen Pharma, INC. | $64.48 | 2023-2024 | Jelmyto |
| Abbvie INC. | $52.74 | 2023-2024 | Mavyret |
| Boston Scientific Corporation | $50.65 | 2022-2023 | Rezum Generator |
| Antares Pharma, INC. | $49.08 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Astellas Pharma US INC | $46.34 | 2024-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.22 | 2023-2024 | Trulance, Xifaxan |
| Baxter Healthcare | $32.18 | 2025 | Tisseel |
| Dendreon Pharmaceuticals LLC | $30.93 | 2024 | Provenge |
| Laborie Medical Technologies Corp. | $27.94 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Merck Sharp & Dohme LLC | $27.04 | 2024 | Keytruda |
| Rochester Medical Corporation | $22.36 | 2019 | |
| Ambu INC. | $21.85 | 2021 | |
| Pfizer INC. | $21.72 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $19.84 | 2019 | |
| Medtronic, INC. | $19.78 | 2022 | |
| Coloplast Corp | $19.43 | 2023 | |
| Axonics, INC. | $18.95 | 2023 | Bulkamid |
| Photocure INC | $18.52 | 2025 | Cysview |
| Convatec INC. | $17.72 | 2025 | |
| Avadel Specialty Pharmaceuticals, LLC | $12.09 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$68,225.49 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Altenbern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.